NECAB2: A Potential Drug Target and Biomarker (G54550)

Target Name: NECAB2

NCBI ID: G54550

NECAB2

NECAB2: A Potential Drug Target and Biomarker

Nucleotide-electrical conductivity-associated protein 2 (NECAB2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. NECAB2 is a transmembrane protein that is expressed in a variety of tissues and cells, including brain, heart, and muscle. It plays a role in the regulation of ion channels and is involved in a wide range of physiological processes, including neuronal communication and muscle function.

Disease-Related Characteristics

NECAB2 has been implicated in several diseases and disorders due to its involvement in various physiological processes. One of the most significant findings related to NECAB2 is its involvement in cancer. NECAB2 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that NECAB2 may be a promising target for cancer therapies.

In addition to its involvement in cancer, NECAB2 has also been linked to a number of neurodegenerative diseases. For example, NECAB2 has been shown to be expressed in the brains of individuals with Alzheimer's disease, and studies have suggested that it may be involved in the development and progression of this disease. Furthermore, NECAB2 has been shown to be involved in the regulation of neurotransmitter release and may play a role in the treatment of psychiatric disorders.

Potential Therapeutic Applications

Given the potential involvement of NECAB2 in a wide range of diseases and disorders, there is significant interest in developing NECAB2 as a drug target or biomarker for therapeutic applications. One of the most promising approaches to target NECAB2 is to use small molecules that can modulate its activity. This approach has been used to develop a number of drugs that have been shown to be effective in treating a wide range of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

For example, a number of studies have shown that NECAB2 is involved in the regulation of ion channels and that modulation of these channels can have a significant impact on cellular behavior. Therefore, drugs that can modulate ion channels and affect NECAB2 activity may be an effective approach to treat a wide range of diseases. One class of drugs that has been shown to be effective in modulating ion channels is known as channel modulators. These drugs work by binding to a specific ion channel and either inhibiting or increasing its activity.

Another approach to developing drugs that target NECAB2 is to use antibodies that are designed to target specific regions of the protein. This approach has been shown to be effective in treating a wide range of diseases, including cancer and neurodegenerative diseases. By using antibodies that are specific for NECAB2, researchers can target the protein and potentially inhibit its activity.

Conclusion

In conclusion, NECAB2 is a protein that has significant potential as a drug target or biomarker for a wide range of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Its involvement in various physiological processes makes it an attractive target for therapeutic applications, and its structure and function have been the subject of intense research in recent years. Further research is needed to fully understand the role of NECAB2 in disease and to develop effective treatments based on its properties.

Protein Name: N-terminal EF-hand Calcium Binding Protein 2

Functions: May act as a signaling scaffold protein that senses intracellular calcium. Can modulate ligand-induced internalization of ADORA2A and coupling efficiency of mGluR5/GRM5; for both receptors may regulate signaling activity such as promoting MAPK1/3 (ERK1/2) activation

The "NECAB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NECAB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets